We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Screening Test Recommended for Heritable Blood Disorder

By LabMedica International staff writers
Posted on 17 Mar 2011
A blood test has been recommended for screening newborns or infants for all forms of an inherited blood disorders as this may reduce morbidity. More...


The hemoglobinopathy is known as Hemoglobin H disease or Alpha Thalassemia and is diagnosed by a variety of tests including high performance liquid chromatography (HPLC). Samples containing more than 25% hemoglobin Bart's should be selected for confirmatory testing.

Over a 15-year period, scientists at the Children's Hospital Oakland, (CA, USA), observed and tested 86 patients, of whom 23 had hemoglobin H Constant Spring mutation (HCS). Diagnosis was confirmed by thin-layer isoelectric focusing, and specific α-globin gene deletions or mutations were identified by multiplexed gap-polymerase-chain-reaction assay. Patients with hemoglobin H have moderately severe anemia because of gene defects leading to insufficient production of hemoglobin. The disorder does not usually cause significant health problems, except in cases of HCS, a severe form of the disease, which often results in life-threatening anemia.

The study provided a previously undocumented natural history of the disease in young children. The patients with HbH exhibited relatively normal growth and development without needing blood transfusions, but patients with HCS were at high-risk for life-threatening anemia even during infancy. There were significant differences in hemoglobin levels between the HbH group and the HCS group and the absolute reticulocyte count and bilirubin level were consistently higher in patients with HCS.

A diagnosis of HCS avoids expending precious time, which could save a young life and money trying to diagnose the problem. The study also demonstrated that hemoglobin H is not restricted to the traditional Asian ethnic populations. Although 81% patients studied had an Asian background, 5% were Hispanic, 3% were African American, and 10% had mixed ancestry.

The study shows that the advanced DNA testing at Children's Hospital Oakland can predict the course of the disease during childhood, which helps to ensure proper treatment for all patients. Hemoglobin H disease arises from the deletion of three of four α-globin genes and HCS is caused by the deletion of two α-globin genes and the Constant Spring mutation. In California, one in 10,000 newborns is diagnosed with hemoglobin H disease. The study was published on February 24, 2011, in the New England Journal of Medicine (NEJM).

Related Links:
Children's Hospital Oakland




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
HPV Test
Allplex HPV28 Detection
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.